ARC
ATRA icon

Absolute Return Capital’s Atara Biotherapeutics ATRA Stock Holding History

Absolute Return Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,014
Closed -$797K – 32
2015
Q3 		$797K Sell
1,014
-184
-15% -$224K 0.05% 309
2015
Q2 		$1.58M Buy
1,198
+239
+25% +$274K 0.06% 287
2015
Q1 		$997K Buy
+959
New +$634K 0.03% 422

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Absolute Return Capital's ATRA Position: Q4 2015 in Review

Absolute Return Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 1,014 shares — an estimated $797K sold.

Absolute Return Capital first reported a position in ATRA in Q1 2015 and held it in 3 quarters. The position peaked at $1.58M in Q2 2015. 84 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

  • Absolute Return Capital reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Absolute Return Capital sold 1,014 Atara Biotherapeutics shares in Q4 2015, an estimated $797K.
  • Absolute Return Capital first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 3 quarters.
  • Absolute Return Capital's Atara Biotherapeutics position peaked at $1.58M in Q2 2015.
  • 84 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on Absolute Return Capital's 13F filing for Q4 2015.